Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study.
Quick Facts
What This Study Found
Semaglutide treatment over 24 months reduced both BMI and muscle mass in older adults with type 2 diabetes. Grip strength initially improved then declined in men, while gait speed decreased in both sexes. Higher doses predicted greater muscle loss.
Key Numbers
220 semaglutide patients, 212 controls. Sarcopenia prevalence 27.7%. Significant reductions in BMI and ASMI in semaglutide group. Gait speed reduced in both sexes. Semaglutide dose, baseline ASMI, and gait speed were independent predictors of muscle loss.
How They Did This
Retrospective cohort study comparing semaglutide-treated elderly T2DM patients to matched controls. Measured ASMI, grip strength, and gait speed over 24 months. Multivariable linear regression for predictors.
Why This Research Matters
Older adults with diabetes are already at risk for muscle wasting. Semaglutide accelerates this loss, especially at higher doses. Doctors need to monitor muscle mass and function in elderly patients on this drug.
What This Study Doesn't Tell Us
Retrospective design. No randomization. Potential confounding by indication (sicker patients may be prescribed semaglutide). No dietary or exercise data collected. Single-center study.
Trust & Context
- Original Title:
- Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study.
- Published In:
- Drug design, development and therapy, 19, 5645-5652 (2025)
- Authors:
- Ren, Qingjuan, Zhi, Lei, Liu, Hongfang
- Database ID:
- RPEP-13243
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13243APA
Ren, Qingjuan; Zhi, Lei; Liu, Hongfang. (2025). Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study.. Drug design, development and therapy, 19, 5645-5652. https://doi.org/10.2147/DDDT.S531778
MLA
Ren, Qingjuan, et al. "Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study.." Drug design, 2025. https://doi.org/10.2147/DDDT.S531778
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide Therapy and Accelerated Sarcopenia in Older Adul..." RPEP-13243. Retrieved from https://rethinkpeptides.com/research/ren-2025-semaglutide-therapy-and-accelerated
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.